---
document_datetime: 2025-07-11 09:51:35
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imfinzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imfinzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 12.436382
conversion_datetime: 2025-12-28 14:45:04.970845
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Imfinzi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0073              | Extension of indication to include IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with resectable muscle invasive bladder cancer (MIBC), | 22/05/2025                          | 02/07/2025                                  | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | based on an ongoing pivotal study D933RC00001 (NIAGARA); this is a phase 3, randomized, open- label, multi-center, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine + cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. The RMP version 13.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes and update the PI according to the Excipients Guideline. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |                       |                                                                                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------|
| II/0064 | Extension of indication to include the treatment in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements for IMFINZI, based on the interim results from study D9106C00001 (AEGEAN); this is a Phase III, double-blind, placebo-controlled, multi- center international study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package                                                               | 27/02/2025 | 31/03/2025 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-0064' |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Leaflet is updated in accordance. Version 11.2 of the RMP has also been approved. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       |                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------|
| II/0069 | Extension of indication to include treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy for IMFINZI, based on results from study D933QC00001 (ADRIATIC); this is a phase III, randomized, double- blind, placebo-controlled, multi-centre, global study to assess the efficacy and safety of durvalumab monotherapy and durvalumab in combination with tremelimumab compared to placebo as consolidation treatment in patients with LS-SCLC whose disease had not progressed following definitive platinum- based chemoradiation therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12.1 of the RMP has also been approved. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to implement editorial changes to Annex II. Furthermore, the PI is brought in line with the latest QRD template version 10.4. C.I.6.a - Change(s) to therapeutic indication(s) - | 30/01/2025 | 12/03/2025 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Imfinzi-H-C-004771-II- 0069 |

<div style=\"page-break-after: always\"></div>

|                     | modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10723 /202404 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12/12/2024 | 12/02/2025 |                       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10723/202404. |
| II/0067/G           | This was an application for a group of variations. B.I.c.z - Container closure system of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product | 17/10/2024 | 12/02/2025 | Annex II              |                                                                                                                                            |
| IB/0072             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/10/2024 | n/a        |                       |                                                                                                                                            |
| WS/2463             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/06/2024 | 26/07/2024 | SmPC, Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|             | Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to include paediatric information based on final results from study D419EC00001 'Phase I/II, Open- Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies'. In addition, the MAH took this opportunity to introduce editorial changes. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0068/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                           | 18/07/2024 | 12/02/2025 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0066     | Update of sections 4.2, 4.4, and 4.8 of the SmPC in order to include rhabdomyolysis as an extension of the myositis and polymyositis medical concept based on post marketing data and literature. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                        | 30/05/2024 | 26/07/2024 | SmPC        | Section 4.2 of the SmPC is amended to include rhabdomyolysis together with immune-mediated myositis/polymyositis in the table for treatment modifications for durvalumab or durvalumab in combination with tremelimumab. Section 4.4 of the SmPC is updated to include rhabdomyolysis in the subsection for other immune- mediated adverse reactions. Rhabdomyolysis is added to the grouped term analysis for calculation of the frequency of Adverse Drug Reaction for |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | myositis (uncommon) in section 4.8 of the SmPC. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2650             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.2 and 4.4 of the SmPC in order to simplify current dosing recommendations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                  | 25/04/2024 | 27/05/2024 | SmPC        | SmPC new text In section 4.4, for Grade 3 or 4 events of immune- mediated pneumonitis, an initial dose of 2-4 mg/kg/day methylprednisolone or equivalent should be initiated followed by a taper. For Immune-mediated colitis/diarrhea, a footnote is included in Table 2 to clarify that in Grade 3 events for patients on IMFINZI + tremelimumab, tremelimumab is to be permanently discontinued while durvalumab can be resumed once the event has resolved. For more information, please refer to the Summary of Product Characteristics.                                                                                               |
| PSUSA/10723 /202304 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/12/2023 | 16/02/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10723/202304.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| WS/2543             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to include paediatric information based on final results from study D419EC00001 'Phase I/II, Open- Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies'. In | 14/12/2023 | 16/02/2024 | SmPC        | Based on the results from study D419EC00001 in children and adolescents, sections 4.2, 5.1, and 5.2 have been updated. The efficacy and safety of of durvalumab in combination with tremelimumab in children were assessed but not established. Currently available data are reported in the SmPC. In the dose-expansion phase, an Overall Response Rate of 5.0% (1/20 patients) was reported in the evaluable for response analysis set. No new safety signals were observed relative to the known safety profiles of durvalumab and tremelimumab in adults. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|           | addition, the MAH took this opportunity to introduce editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                 |                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------|
| II/0057   | Extension of indication to include IMFINZI as monotherapy for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from study D419CC00002 (HIMALAYA); this was a randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (HIMALAYA). As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 9.1 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 12/10/2023 | 15/11/2023 | SmPC and PL     | Please refer to Scientific Discussion: Imfinzi EMEA/H/C/004771/II/0057. |
| IAIN/0060 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/07/2023 | 15/11/2023 | Annex II and PL |                                                                         |
| IA/0059   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/05/2023 | n/a        |                 |                                                                         |

<div style=\"page-break-after: always\"></div>

| R/0055   | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/02/2023   | 24/04/2023   | SmPC, Annex II and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Imfinzi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0056  | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                  | 30/01/2023   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0052  | Update of section 4.2 of the SmPC in order to update the recommendation for dose modification for 'other immune-mediated adverse reactions' as well as immune-mediated encephalitis, meningitis, Guillain- Barré syndrome and myasthenia gravis based on the National Comprehensive Cancer Network (NCCN) guideline recommendations (2022). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/12/2022   | 30/01/2023   | SmPC                    | SmPC new text The table on recommended treatment modifications in case of immune-mediated adverse reactions was updated as follows: immune-mediated meningitis has been added as a separate row, requiring intervention and permanent discontinuation for Grade 3 or 4, and intervention and withholding dose for Grade 2; immune-mediated encephalitis has been added as a separate row, requiring intervention and permanent discontinuation for Grade 2 - 4; immune-mediated Guillain-Barré syndrome has been added as a separate row, requiring intervention and permanent discontinuation for Grade 2 - 4; 'myasthenia gravis' was changed to 'immune-mediated myasthenia gravis', requiring intervention and permanent discontinuation for Grade 2 - 4; other immune-mediated adverse reactions row was updated to require intervention and withholding dose for Grade 2 or 3. For more information, please refer to the Summary of Product Characteristics. |
| II/0045  | Extension of indication to include IMFINZI in combination with tremelimumab for the first line                                                                                                                                                                                                                                                                                                                                                                | 15/12/2022   | 30/01/2023   | SmPC and PL             | Please refer to Scientific Discussion: Imfinzi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | treatment of adults with advanced or unresectable hepatocellular carcinoma (uHCC), based on final results from Study D419CC00002 (HIMALAYA); This was a randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 8.1 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             | EMEA/H/C/004771/II/0045.                                                |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------|
| II/0041 | Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) positive mutations, based on final results from Study D419MC00004 (POSEIDON); This was a Phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy and safety of tremelimumab and durvalumab or durvalumab in                                                                                                                                                                                                                                                                                                                              | 15/12/2022 | 30/01/2023 | SmPC and PL | Please refer to Scientific Discussion: Imfinzi EMEA/H/C/004771/II/0041. |

<div style=\"page-break-after: always\"></div>

|         | combination with platinum based chemotherapy for first-line treatment in patients with metastatic NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2. Version 8.1 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             |                                                                         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------|
| II/0054 | Submission of final report from non-clinical study ONC4736-PB-0401 (Profiling of Biomarkers Relevant to Immunotherapies in Pediatric Solid Tumors). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/01/2023 | n/a        |             | Not applicable                                                          |
| II/0046 | Extension of indication to include IMFINZI in combination with gemcitabine and cisplatin for the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC), based on the second interim analysis from the ongoing pivotal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10/11/2022 | 16/12/2022 | SmPC and PL | Please refer to Scientific Discussion: Imfinzi EMEA/H/C/004771/II/0046. |

<div style=\"page-break-after: always\"></div>

|                     | study D933AC00001 (TOPAZ-1); a phase III randomized, double-blind, placebo-controlled, multi- regional, international study conducted to assess the efficacy and safety of durvalumab in combination with the current standard of care Gemcitabine/Cisplatin for the first-line treatment of patients with locally advanced or metastatic BTC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package leaflet has been updated accordingly. Version 7.2 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IAIN/0058           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/12/2022 | 30/01/2023 | SmPC and PL |                                   |
| PSUSA/10723 /202204 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/12/2022 | n/a        |             | PRAC Recommendation - maintenance |
| II/0051             | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/11/2022 | n/a        |             |                                   |
| IA/0053             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18/10/2022 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| II/0050             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                | 29/09/2022   | 16/12/2022   | SmPC        |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10723 /202110 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/06/2022   | 22/08/2022   | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10723/202110. |
| IB/0048             | B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                                                                                                                                                                                                           | 10/08/2022   | n/a          |             |                                                                                                                                            |
| IB/0047/G           | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 08/08/2022   | n/a          |             |                                                                                                                                            |
| II/0034             | Update of sections 4.4 and 4.8 of the SmPC in order to reflect the outcome of the re-defined process to identify and calculate immune-mediated Adverse Event (imAE) rates from clinical study and pooled datasets within the durvalumab development programmes. In addition, the MAH implemented minor editorial corrections to sections 4.4 and 5.1 of                                                                                                                          | 23/06/2022   | 22/08/2022   | SmPC        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                            |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| II/0039/G           | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/04/2022 | 13/06/2022 | SmPC        |                                                                                                                                            |
| IB/0043             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                           | 20/04/2022 | n/a        |             |                                                                                                                                            |
| IAIN/0044/G         | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                        | 06/04/2022 | 13/06/2022 | SmPC and PL |                                                                                                                                            |
| PSUSA/10723 /202104 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                               | 16/12/2021 | 28/02/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10723/202104. |

<div style=\"page-break-after: always\"></div>

| II/0040   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                             | 17/02/2022   | 13/06/2022   | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0036   | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/02/2022   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0038/G | This was an application for a group of variations. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                                                        | 08/12/2021   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0037   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                           | 29/10/2021   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0030/G | This was an application for a group of variations. Update of sections 4.2. and 4.4 the SmPC in order to change posology recommendations for management of immune-mediated adverse reactions and amend an existing warning on Immune-mediated type 1 diabetes mellitus to include diabetic ketoacidosis; these changes are based on case studies reports, updated guidelines. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make some minor corrections to section 4.8 of the SmPC. | 16/09/2021   | 19/10/2021   | SmPC and PL | Changes to Section 4.2 were made to adjust treatment modifications and management recommendations for adverse reactions including: *Changes to corticosteroid dosing from 1 - 4 mg/kg/day to 1 - 2 mg/kg/day for pneumonitis, myositis/polymyositis, myocarditis, myasthenia gravis, and other immune- mediated adverse events *clarification on how to manage myasthenia gravis and Gastrointestinal immune-mediated adverse events *change to the timing for initiation of additional immunosuppressive therapy in steroid refractory from 3 - 5 days to 2 - 3. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                    |            |            |                       | A warning that immune-mediated Type 1 diabetes mellitus can present with diabetic ketoacidosis which can be fatal if not detected early was included in section 4.4.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0035           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                         | 22/09/2021 | 28/02/2022 | SmPC and PL           |                                                                                                                                                                        |
| II/0032             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                  | 16/09/2021 | n/a        |                       |                                                                                                                                                                        |
| IB/0031/G           | This was an application for a group of variations. B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data) A.7 - Administrative change - Deletion of manufacturing sites | 07/07/2021 | 19/10/2021 | SmPC, Annex II and PL | The product information was updated to extend the shelf life after diluation and the manufacturers responsible for batch release were updated..                        |
| PSUSA/10723 /202010 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                               | 10/06/2021 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                      |
| II/0028             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                          | 29/04/2021 | n/a        |                       |                                                                                                                                                                        |
| IB/0029             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                   | 24/03/2021 | n/a        |                       |                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| II/0026   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/02/2021   | 19/10/2021   | SmPC                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023   | Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen of 1500 mg every 4 weeks (Q4W) for the approved indication of the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours express PD- L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy. The RMP version 4.1 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 10/12/2020   | 11/01/2021   | SmPC                  | Durvalumab doses of 10 mg/kg every 2 weeks or 1500 mg every 4 weeks were evaluated in NSCLC and ES-SCLC clinical studies. Based on the modeling and simulation of exposure, exposure-safety relationships and exposure- efficacy data comparisons, there are no anticipated clinically significant differences in efficacy and safety between durvalumab doses of 10 mg/kg every 2 weeks or 1500 mg every 4 weeks in locally advanced NSCLC. Patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to durvalumab 10 mg/kg every 2 weeks or 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 30 kg. |
| IB/0025/G | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                       | 11/12/2020   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0024   | Update of sections 4.4 and 4.8 of the SmPC in order to add immune thrombocytopenia to the list of adverse drug reactions (ADRs) with frequency (rare) following the MAH internal review; the Package Leaflet (PL) is updated accordingly. The MAH took                                                                                                                                                                                                                                                                                                      | 10/12/2020   | 11/01/2021   | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | the opportunity to correct information in the PL and to make editorial changes to the names of the manufacturer in Annex II and to units in Annex IIIA. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------|
| PSUSA/10723 /202004 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/11/2020 | n/a        |             | PRAC Recommendation - maintenance                                        |
| II/0014/G           | This was an application for a group of variations. Extension of Indication to include the use of IMFINZI in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC were updated. The proposed indication is supported by study D419QC00001 (CASPIAN), an ongoing Phase III randomised, multicentre, open-label, comparative study designed to determine the efficacy and safety of durvalumab, or durvalumab and tremelimumab, in combination with etoposide and platinum-based chemotherapy (EP) for the first-line treatment of patients with ES- SCLC. In addition, the MAH proposes to revise sections 4.4 and 4.8 of the SmPC to update the safety information based on the Durvalumab Pan-Tumour Pool, a safety dataset comprising of 9 clinical studies | 23/07/2020 | 27/08/2020 | SmPC and PL | Please refer to Scientific Discussion Imfinzi EMEA/H/C/004771/II/0014/G. |

<div style=\"page-break-after: always\"></div>

|                     | building on the existing safety database and summarising the safety information for durvalumab monotherapy characterised across tumour types in the durvalumab clinical program to date. The Package Leaflet is updated in accordance. The RMP version 2 has also been agreed. The MAH also took the opportunity of this group of variations to update the PI in line with QRD template v10.1. The group of variations leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10723 /201910 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/05/2020 | 27/07/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10723/201910. |
| IAIN/0021           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13/05/2020 | 27/07/2020 | SmPC and PL |                                                                                                                                            |
| IB/0020             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/04/2020 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0018             | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                              | 29/04/2020   | n/a        |                       |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0019             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                               | 16/03/2020   | n/a        |                       |                                                                                                                                            |
| PSUSA/10723 /201904 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                                                                                                                                                                                                       | 12/12/2019   | 21/02/2020 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10723/201904. |
| IAIN/0015           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                 | 10/12/2019   | 21/02/2020 | SmPC and PL           |                                                                                                                                            |
| IB/0013/G           | This was an application for a group of variations. B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation | 04/12/2019   | n/a        |                       |                                                                                                                                            |
| IB/0012             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                         | 02/12/2019   | n/a        |                       |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0011             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                           | 11/10/2019   | n/a        |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| II/0009             | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                | 12/09/2019   | 21/02/2020 | SmPC and PL     |                                   |
| PSUSA/10723 /201810 | Periodic Safety Update EU Single assessment - durvalumab                                                                                                                                                                               | 16/05/2019   | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0008           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 08/04/2019   | 21/02/2020 | Annex II and PL |                                   |
| II/0003             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                  | 07/03/2019   | n/a        |                 |                                   |
| IB/0007             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                           | 28/02/2019   | n/a        |                 |                                   |
| IB/0006             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                             | 21/02/2019   | n/a        |                 |                                   |
| II/0004             | B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period                                                                                                                              | 31/01/2019   | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|         | of a biological/immunological AS not in accordance with an approved stability protocol                                                 |            |     |                             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------|
| II/0001 | B.II.g.2 - Introduction of a post approval change to the finished product                                                              | 13/12/2018 | n/a | management protocol related |
| IB/0002 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 30/11/2018 | n/a |                             |